GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » Shiller PE Ratio

Tenax Therapeutics (Tenax Therapeutics) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Tenax Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Tenax Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Shiller PE Ratio Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tenax Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tenax Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Tenax Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Shiller PE Ratio falls into.



Tenax Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Tenax Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Tenax Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.12/131.7762*131.7762
=-3.120

Current CPI (Mar. 2024) = 131.7762.

Tenax Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -12,040.600 100.023 -15,862.965
201407 -2,473.130 100.520 -3,242.131
201410 -4,618.410 100.176 -6,075.303
201501 -3,266.910 98.604 -4,365.981
201504 -5,680.060 99.824 -7,498.194
201507 -3,456.150 100.691 -4,523.142
201510 -4,014.090 100.346 -5,271.355
201603 -6,106.680 100.470 -8,009.474
201606 -5,286.110 101.688 -6,850.197
201609 -4,867.490 101.861 -6,297.006
201612 -33,767.000 101.863 -43,683.183
201703 -3,713.820 102.862 -4,757.754
201706 -3,385.680 103.349 -4,316.942
201709 -1,399.310 104.136 -1,770.727
201712 -1,523.510 104.011 -1,930.201
201803 -1,313.840 105.290 -1,644.351
201806 -2,056.790 106.317 -2,549.324
201809 -1,678.670 106.507 -2,076.947
201812 -4,028.500 105.998 -5,008.216
201903 -528.000 107.251 -648.741
201906 -448.000 108.070 -546.276
201909 -528.000 108.329 -642.280
201912 -640.000 108.420 -777.870
202003 -608.000 108.902 -735.710
202006 -368.000 108.767 -445.848
202009 -288.000 109.815 -345.596
202012 -352.000 109.897 -422.080
202103 -2,624.000 111.754 -3,094.113
202106 -160.000 114.631 -183.930
202109 -240.000 115.734 -273.266
202112 -60.800 117.630 -68.112
202203 -172.800 121.301 -187.723
202206 -181.600 125.017 -191.419
202209 -177.600 125.227 -186.889
202212 -69.510 125.222 -73.148
202303 -12.100 127.348 -12.521
202306 -4.000 128.729 -4.095
202309 -6.400 129.860 -6.494
202312 -11.840 129.419 -12.056
202403 -3.120 131.776 -3.120

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Tenax Therapeutics  (NAS:TENX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Tenax Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (Tenax Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

Tenax Therapeutics (Tenax Therapeutics) Headlines

From GuruFocus

Tenax Therapeutics, Inc. Expands Board of Directors

By Business Wire Business Wire 03-02-2021

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

By GuruFocusNews GuruFocusNews 01-31-2022